

# Gernot Zissel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1447560/publications.pdf>

Version: 2024-02-01

97  
papers

5,830  
citations

70961

41  
h-index

76769

74  
g-index

102  
all docs

102  
docs citations

102  
times ranked

6989  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Cluster of Beryllium Sensitization Traced to the Presence of Beryllium in Concrete Dust. <i>Chest</i> , 2021, 159, 1084-1093.	0.4	14
2	Surveillance Bronchoscopy for the Care of Lung Transplant Recipients: A Retrospective Single Center Analysis. <i>Transplantation Proceedings</i> , 2021, 53, 265-272.	0.3	4
3	Analysis of single nucleotide polymorphisms in chronic beryllium disease. <i>Respiratory Research</i> , 2021, 22, 107.	1.4	1
4	Insights into immunometabolism: A dataset correlating the 18FDG PET/CT maximum standard uptake value of the primary tumor with the CCL18 serum level in non-small cell lung cancer. <i>Data in Brief</i> , 2021, 35, 106859.	0.5	3
5	Development of a new methodology to determine size differences of nanoparticles with nanoparticle tracking analysis. <i>Applied Nanoscience (Switzerland)</i> , 2021, 11, 2129-2141.	1.6	4
6	Response. <i>Chest</i> , 2021, 159, 2509-2510.	0.4	0
7	Vasoactive Intestinal Peptide in Checkpoint Inhibitor-Induced Pneumonitis. <i>New England Journal of Medicine</i> , 2020, 382, 2573-2574.	13.9	17
8	Interaction Between CCL18 and GPR30 Differs from the Interaction Between Estradiol and GPR30. <i>Anticancer Research</i> , 2020, 40, 3097-3108.	0.5	3
9	Safety and efficacy of abatacept in patients with treatment-resistant SARCoidosis (ABASARC) protocol for a multi-center, single-arm phase IIa trial. <i>Contemporary Clinical Trials Communications</i> , 2020, 19, 100575.	0.5	10
10	Bronchoalveolar Lavage Fluid Reflects a TH1-CD21 <sup>low</sup> B-Cell Interaction in COVID-Related Interstitial Lung Disease. <i>Frontiers in Immunology</i> , 2020, 11, 616832.	2.2	12
11	Kinetics of Torque Teno Virus-DNA Plasma Load Predict Rejection in Lung Transplant Recipients. <i>Transplantation</i> , 2019, 103, 815-822.	0.5	40
12	Human alveolar epithelial cells type II are capable of TGF $\beta$ -dependent epithelial-mesenchymal-transition and collagen-synthesis. <i>Respiratory Research</i> , 2018, 19, 138.	1.4	52
13	Turning back the Wheel: Inducing Mesenchymal to Epithelial Transition via Wilms Tumor 1 Knockdown in Human Mesothelioma Cell Lines to Influence Proliferation, Invasiveness, and Chemotaxis. <i>Pathology and Oncology Research</i> , 2017, 23, 723-730.	0.9	7
14	Sarcoidosis: Drugs under Investigation. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017, 38, 532-537.	0.8	5
15	<i>Atopobium</i> and <i>Fusobacterium</i> as novel candidates for sarcoidosis-associated microbiota. <i>European Respiratory Journal</i> , 2017, 50, 1600746.	3.1	46
16	P2Y6 Receptor Activation Promotes Inflammation and Tissue Remodeling in Pulmonary Fibrosis. <i>Frontiers in Immunology</i> , 2017, 8, 1028.	2.2	27
17	Is serum level of CC chemokine ligand 18 a biomarker for the prediction of radiation induced lung toxicity (RILT)? <i>PLoS ONE</i> , 2017, 12, e0185350.	1.1	5
18	The purinergic receptor subtype P2Y2 mediates chemotaxis of neutrophils and fibroblasts in fibrotic lung disease. <i>Oncotarget</i> , 2017, 8, 35962-35972.	0.8	28

#	ARTICLE	IF	CITATIONS
19	Association Study for 26 Candidate Loci in Idiopathic Pulmonary Fibrosis Patients from Four European Populations. <i>Frontiers in Immunology</i> , 2016, 7, 274.	2.2	18
20	Functional Toll-Like Receptor 9 Expression and CXCR3 Ligand Release in Pulmonary Sarcoidosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2016, 55, 749-757.	1.4	29
21	Specific antigen(s) in sarcoidosis: a link to autoimmunity?. <i>European Respiratory Journal</i> , 2016, 47, 707-709.	3.1	13
22	Local Concentrations of CC-Chemokine-Ligand 18 Correlate with Tumor Size in Non-small Cell Lung Cancer and Are Elevated in Lymph Node-positive Disease. <i>Anticancer Research</i> , 2016, 36, 4667-4672.	0.5	8
23	Uridine supplementation exerts anti-inflammatory and anti-fibrotic effects in an animal model of pulmonary fibrosis. <i>Respiratory Research</i> , 2015, 16, 105.	1.4	28
24	Macrophage Activation in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. <i>PLoS ONE</i> , 2015, 10, e0116775.	1.1	170
25	Altered purinergic signaling in the tumor associated immunologic microenvironment in metastasized non-small-cell lung cancer. <i>Lung Cancer</i> , 2015, 90, 516-521.	0.9	35
26	Cellular Players in the Immunopathogenesis of Sarcoidosis. <i>Clinics in Chest Medicine</i> , 2015, 36, 549-560.	0.8	39
27	Are bronchoalveolar lavages a good source for microbial profiling? Differences between throat and bronchoalveolar lavage microbiomes. <i>Journal of Medical Microbiology</i> , 2015, 64, 948-951.	0.7	12
28	The chemokine CCL18 characterises <i>Pseudomonas</i> infections in cystic fibrosis lung disease. <i>European Respiratory Journal</i> , 2014, 44, 1608-1615.	3.1	16
29	Cellular Activation in the Immune Response of Sarcoidosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2014, 35, 307-315.	0.8	25
30	mRNA and miRNA analyses in cytologically positive endobronchial ultrasound-guided transbronchial needle aspiration: Implications for molecular staging in lung cancer patients. <i>Cancer Cytopathology</i> , 2014, 122, 292-298.	1.4	11
31	Soluble CD90 as a potential marker of pulmonary involvement in systemic sclerosis. <i>Arthritis Care and Research</i> , 2013, 65, 281-287.	1.5	15
32	Genome-wide association analysis reveals 12q13.3-q14.1 as new risk locus for sarcoidosis. <i>European Respiratory Journal</i> , 2013, 41, 888-900.	3.1	43
33	CC-Chemokine Ligand 18 Induces Epithelial to Mesenchymal Transition in Lung Cancer A549 Cells and Elevates the Invasive Potential. <i>PLoS ONE</i> , 2013, 8, e53068.	1.1	45
34	Lung Collagens Perpetuate Pulmonary Fibrosis via CD204 and M2 Macrophage Activation. <i>PLoS ONE</i> , 2013, 8, e81382.	1.1	102
35	Tumor-Cell Co-Culture Induced Alternative Activation of Macrophages Is Modulated by Interferons <i>In Vitro</i> . <i>Journal of Interferon and Cytokine Research</i> , 2012, 32, 169-177.	0.5	30
36	A Novel Sarcoidosis Risk Locus for Europeans on Chromosome 11q13.1. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 877-885.	2.5	51

#	ARTICLE	IF	CITATIONS
37	CCL18 â€” Potential Biomarker of Fibroinflammatory Activity in Chronic Periaortitis. <i>Journal of Rheumatology</i> , 2012, 39, 1407-1412.	1.0	14
38	Pathogenesis of sarcoidosis. <i>Presse Medicale</i> , 2012, 41, e275-e287.	0.8	44
39	Roflumilast-N-oxide Induces Surfactant Protein Expression in Human Alveolar Epithelial Cells Type II. <i>PLoS ONE</i> , 2012, 7, e38369.	1.1	5
40	Serum Level of CC-Chemokine Ligand 18 Is Increased in Patients with Non-Small-Cell Lung Cancer and Correlates with Survival Time in Adenocarcinomas. <i>PLoS ONE</i> , 2012, 7, e41746.	1.1	29
41	Purinergic Receptor Type 6 Contributes to Airway Inflammation and Remodeling in Experimental Allergic Airway Inflammation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 215-223.	2.5	85
42	P2X <sub>7</sub> Receptor Signaling in the Pathogenesis of Smoke-Induced Lung Inflammation and Emphysema. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2011, 44, 423-429.	1.4	130
43	Generation and evaluation of a monoclonal antibody, designated MA <sub>DL</sub> , as a new specific marker for adenocarcinomas of the lung. <i>British Journal of Cancer</i> , 2011, 105, 673-681.	2.9	6
44	Alternatively activated alveolar macrophages in pulmonary fibrosisâ€”mediator production and intracellular signal transduction. <i>Clinical Immunology</i> , 2010, 137, 89-101.	1.4	268
45	Local administration of uridine suppresses the cardinal features of asthmatic airway inflammation. <i>Clinical and Experimental Allergy</i> , 2010, 40, 1552-1560.	1.4	11
46	Extracellular Adenosine Triphosphate and Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 928-934.	2.5	174
47	Purinergic Receptor Inhibition Prevents the Development of Smoke-Induced Lung Injury and Emphysema. <i>Journal of Immunology</i> , 2010, 185, 688-697.	0.4	119
48	Immunologic Response of Sarcoidosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2010, 31, 390-403.	0.8	82
49	Inhaled Vasoactive Intestinal Peptide Exerts Immunoregulatory Effects in Sarcoidosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 540-548.	2.5	146
50	Serum CC-Chemokine Ligand 18 Concentration Predicts Outcome in Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 717-723.	2.5	290
51	The Hidden Macrophage. <i>Respiration</i> , 2009, 77, 129-131.	1.2	0
52	CCL18 Production is Decreased in Alveolar Macrophages from Cigarette Smokers. <i>Inflammation</i> , 2009, 32, 163-168.	1.7	16
53	Essential Role of Osteopontin in Smoking-Related Interstitial Lung Diseases. <i>American Journal of Pathology</i> , 2009, 174, 1683-1691.	1.9	59
54	Inflammatory markers in exhaled breath condensate following lung resection for bronchial carcinoma. <i>Respirology</i> , 2008, 13, 1022-1027.	1.3	12

#	ARTICLE	IF	CITATIONS
55	Interleukin-13 acts as an apoptotic effector on lung epithelial cells and induces pro-fibrotic gene expression in lung fibroblasts. <i>Clinical and Experimental Allergy</i> , 2008, 38, 619-628.	1.4	43
56	Genetics of Sarcoidosis. <i>Clinics in Chest Medicine</i> , 2008, 29, 391-414.	0.8	80
57	Activation of Human Alveolar Macrophages via P2 Receptors: Coupling to Intracellular Ca <sup>2+</sup> Increases and Cytokine Secretion. <i>Journal of Immunology</i> , 2008, 181, 2181-2188.	0.4	57
58	Phenotyping Sarcoidosis from a Pulmonary Perspective. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 177, 330-336.	2.5	137
59	Serotonergic Receptors on Human Airway Epithelial Cells. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2007, 36, 85-93.	1.4	65
60	Sarcoidosis-Immunopathogenetic Concepts. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2007, 28, 003-014.	0.8	86
61	Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. <i>European Respiratory Journal</i> , 2007, 29, 976-985.	3.1	315
62	IL-10-producing monocytes differentiate to alternatively activated macrophages and are increased in atopic patients. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 119, 464-471.	1.5	55
63	CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2007, 56, 1685-1693.	6.7	202
64	Pulmonary TH2 response in <i>Pseudomonas aeruginosa</i> -infected patients with cystic fibrosis. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 117, 204-211.	1.5	172
65	A Vicious Circle of Alveolar Macrophages and Fibroblasts Perpetuates Pulmonary Fibrosis via CCL18. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 781-792.	2.5	403
66	Functional characterization of histamine receptor subtypes in a human bronchial epithelial cell line. <i>International Journal of Molecular Medicine</i> , 2006, 18, 925.	1.8	7
67	Interleukin-18 expression by alveolar epithelial cells type II in tuberculosis and sarcoidosis. <i>FEMS Immunology and Medical Microbiology</i> , 2006, 46, 30-38.	2.7	19
68	Chemokines Indicate Allergic Bronchopulmonary Aspergillosis in Patients with Cystic Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 1370-1376.	2.5	83
69	Genotype-corrected reference values for serum angiotensin-converting enzyme. <i>European Respiratory Journal</i> , 2006, 28, 1085-1091.	3.1	66
70	Diagnoses of chronic beryllium disease within cohorts of sarcoidosis patients. <i>European Respiratory Journal</i> , 2006, 27, 1190-1195.	3.1	116
71	Functional characterization of histamine receptor subtypes in a human bronchial epithelial cell line. <i>International Journal of Molecular Medicine</i> , 2006, 18, 925-31.	1.8	20
72	The P2Y <sub>14</sub> Receptor of Airway Epithelial Cells. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2005, 33, 601-609.	1.4	90

#	ARTICLE	IF	CITATIONS
73	CCR2 and CXCR3 agonistic chemokines are differently expressed and regulated in human alveolar epithelial cells type II. <i>Respiratory Research</i> , 2005, 6, 75.	1.4	43
74	A role for MCP-1/CCR2 in interstitial lung disease in children. <i>Respiratory Research</i> , 2005, 6, 93.	1.4	44
75	Pulmonary chemokines and their receptors differentiate children with asthma and chronic cough. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 115, 728-736.	1.5	70
76	Acute lung affection in an endurance-trained man under amiodarone medication. <i>GMS German Medical Science</i> , 2005, 3, Doc03.	2.7	0
77	The Serotonergic Receptors of Human Dendritic Cells: Identification and Coupling to Cytokine Release. <i>Journal of Immunology</i> , 2004, 172, 6011-6019.	0.4	190
78	HOPE-Fixation Enables Improved PCR-Based Detection and Differentiation of Mycobacterium tuberculosis Complex in Paraffin-Embedded Tissues. <i>Pathology Research and Practice</i> , 2003, 199, 619-623.	1.0	23
79	Alveolar macrophages are the main source for tumour necrosis factor- $\alpha$ in patients with sarcoidosis. <i>European Respiratory Journal</i> , 2003, 21, 421-428.	3.1	97
80	Systemic Immune Cell Activation in a Subgroup of Patients with Idiopathic Pulmonary Fibrosis. <i>Respiration</i> , 2003, 70, 262-269.	1.2	34
81	Human alveolar epithelial cells induce nitric oxide synthase-2 expression in alveolar macrophages. <i>European Respiratory Journal</i> , 2002, 19, 672-683.	3.1	38
82	Prostaglandin E2 reinforces the activation of Ras signal pathway in lung adenocarcinoma cells via EP3. <i>FEBS Letters</i> , 2002, 518, 154-158.	1.3	58
83	Exaggerated TNF $\alpha$ release of alveolar macrophages in corticosteroid resistant sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2002, 19, 185-90.	0.2	64
84	Formation of Granulomas in the Lungs of Severe Combined Immunodeficient Mice after Infection with Bacillus Calmette-Guerin. <i>American Journal of Pathology</i> , 2001, 158, 1890-1891.	1.9	9
85	Accessory Function and Costimulatory Molecule Expression of Alveolar Macrophages in Patients with Pulmonary Tuberculosis. <i>Immunobiology</i> , 2000, 201, 450-460.	0.8	6
86	Analysis of the Kveim-Siltzbach Test Reagent for Bacterial DNA. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1999, 159, 1981-1984.	2.5	33
87	Pharmacological modulation of the IFN $\gamma$ -induced accessory function of alveolar macrophages and peripheral blood monocytes. <i>Inflammation Research</i> , 1999, 48, 662-668.	1.6	12
88	POLYMORPHISMS AT POSITION -308 IN THE PROMOTER REGION OF THE TNF- $\alpha$ AND IN THE FIRST INTRON OF THE TNF- $\beta$ GENES AND SPONTANEOUS AND LIPOPOLYSACCHARIDE-INDUCED TNF- $\alpha$ RELEASE IN SARCOIDOSIS. <i>Cytokine</i> , 1999, 11, 882-887.	1.4	55
89	Sarcoidosis: historical perspective and immunopathogenesis (part I). <i>Respiratory Medicine</i> , 1998, 92, 126-139.	1.3	24
90	Serum Level of Interleukin 8 Is Elevated in Idiopathic Pulmonary Fibrosis and Indicates Disease Activity. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1998, 157, 762-768.	2.5	120

#	ARTICLE	IF	CITATIONS
91	Sarcoidosis: TNF- $\alpha$ Release from Alveolar Macrophages and Serum Level of sIL-2R Are Prognostic Markers. American Journal of Respiratory and Critical Care Medicine, 1997, 156, 1586-1592.	2.5	228
92	TCR V $\beta$ Families in T Cell Clones from Sarcoid Lung Parenchyma, BAL, and Blood. American Journal of Respiratory and Critical Care Medicine, 1997, 156, 1593-1600.	2.5	22
93	Anti- <i>Borrelia burgdorferi</i> immunoglobulin seroprevalence in pulmonary sarcoidosis: a negative report. European Respiratory Journal, 1997, 10, 1356-1358.	3.1	22
94	Shed soluble ICAM-1 molecules in bronchoalveolar lavage cell supernatants and serum of patients with pulmonary sarcoidosis. Lung, 1997, 175, 105-116.	1.4	20
95	Anti-inflammatory cytokine release by alveolar macrophages in pulmonary sarcoidosis.. American Journal of Respiratory and Critical Care Medicine, 1996, 154, 713-719.	2.5	83
96	Induction of accessory cell function of human alveolar macrophages by inhalation of human natural interleukin-2. Cancer Immunology, Immunotherapy, 1996, 42, 122-126.	2.0	11
97	Spontaneous interleukin 2 release of bronchoalveolar lavage cells in sarcoidosis is a codeterminator of prognosis. Lung, 1996, 174, 243-53.	1.4	17